IL1B and coronary artery disorder: The limitations of this study are as follows: it included patients with AMI, but it is unknown whether its conclusions can be extended to patients with stable coronary heart disease; the pathogenesis of CVDs is complex, and the intervention of one molecular target in the inflammatory pathway may not be sufficient; besides, as the upstream of the inflammatory response, inhibition of IL-1β by canakinumab-induced severe infection is an adverse effect that cannot be ignored.